8JIX image
Deposition Date 2023-05-29
Release Date 2024-03-06
Last Version Date 2025-05-28
Entry Detail
PDB ID:
8JIX
Title:
Crystal structure of the Bagaza virus helicase and structure-based discovery of a novel inhibitor
Biological Source:
Source Organism:
Bagaza virus (Taxon ID: 64290)
Host Organism:
Method Details:
Experimental Method:
Resolution:
1.71 Å
R-Value Free:
0.20
R-Value Work:
0.18
Space Group:
P 21 21 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Genome polyprotein
Chain IDs:A
Chain Length:437
Number of Molecules:1
Biological Source:Bagaza virus
Primary Citation
Structure-based discovery of dual-target inhibitors of the helicase from bagaza virus.
Int.J.Biol.Macromol. 294 139536 139536 (2025)
PMID: 39765299 DOI: 10.1016/j.ijbiomac.2025.139536

Abstact

Bagaza virus (BAGV) is a mosquito-borne flavivirus and has caused significant avian death in many regions, and also garnered recognition as a significant human pathogen causing diseases like encephalitis. The genome of BAGV encodes ten proteins including three structural proteins and seven nonstructural proteins. The C-terminus of the BAGV NS3 helicase serves as a helicase during BAGV replication, aiding in ATP hydrolysis and unwinding of double-stranded RNA. Here we determined the crystal structure of BAGV helicase and revealed the NTP and RNA binding pockets in the helicase which may be used for exploiting antiviral therapeutics. Using structure-based virtual screening, we discovered 20 compounds targeting both NTP and RNA binding pockets of the helicase. Molecular docking, mutation analysis, isothermal calorimetry (ITC) and the ATPase activity assay demonstrated that epigallocatechin-3-gallate (EGCG), and other top three screened compounds (Quercitrin, Citicoline sodium, Isochlorogenic acid C), showed binding affinities for both the NTP binding site and the RNA binding site of BAGV helicase, and inhibited the ATPase activity of the helicase. Taken together, our discovery of dual-target inhibitors provides a viable strategy for advancing innovative therapies against BAGV, as well as other flaviviruses.

Legend

Protein

Chemical

Disease

Primary Citation of related structures